Entest (ETNI) 10-Q 15 Jul 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	May 31, 2019	Jul. 08, 2019
Document And Entity Information
Entity Registrant Name	ENTEST GROUP, INC.
Entity Central Index Key	0001449447
Document Type	10-Q
Document Period End Date	May 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--08-31
Entity's Reporting Status Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	true
Entity Common Stock, Shares Outstanding		49,170,472
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019

Balance Sheets (unaudited)

Balance Sheets (unaudited) - USD ($)	May 31, 2019	Aug. 31, 2018
Current Assets
Cash		$ 267
Accrued Interest Receivable	$ 1,040	1,040
Prepaid expenses		8,000
Total Current Assets	1,040	9,307
Total Assets	1,040	9,307
Current Liabilities
Accounts payable and accrued expenses	13,305	218,417
Unearned rental income		17,000
Due to related party	13,627
Note payable		19,601
Total Current Liabilities	26,932	255,018
Total Liabilities	26,932	255,018
Stockholders' Deficit
Common stock- 500,000,000 shares authorized; $0.0001 par value 49,170,472 shares issued and outstanding	4,917	4,917
Additional paid in capital	9,025,314	9,003,892
Accumulated deficit	(10,057,729)	(10,256,126)
Total Stockholders' Deficit	(25,892)	(245,711)
Total liabilities and Stockholder's Deficit	1,040	9,307
Series AA
Stockholders' Deficit
Preferred Stock
Series AAA
Stockholders' Deficit
Preferred Stock
Series B
Stockholders' Deficit
Preferred Stock	73	73
Non-Voting
Stockholders' Deficit
Preferred Stock	$ 1,001,533	$ 1,001,533

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	May 31, 2019	Nov. 15, 2018	Aug. 31, 2018
Common stock, par value	$ 0.0001		$ 0.0001
Common stock, authorized	500,000,000		500,000,000
Common stock, issued	49,170,472		49,170,472
Common stock, shares outstanding	49,170,472	49,170,472	49,170,472
Preferred stock, par value	$ 0.0001
Preferred stock, issued	5,000,000
Series AA
Preferred stock, par value	$ 0.0001		$ 0.0001
Preferred stock, authorized	100,000		100,000
Preferred stock, issued	667		667
Preferred stock, shares outstanding	667	667	667
Series AAA
Preferred stock, par value	$ 0.0001		$ 0.0001
Preferred stock, authorized	300,000		300,000
Preferred stock, issued	534		534
Preferred stock, shares outstanding	534	534	534
Non-Voting
Preferred stock, par value	$ 1		$ 1
Preferred stock, authorized	3,000,000		3,000,000
Preferred stock, issued	1,001,533		1,001,533
Preferred stock, shares outstanding	1,001,533	1,001,533	1,001,533
Series B
Preferred stock, par value	$ 0.0001		$ 0.0001
Preferred stock, authorized	4,400,000		4,400,000
Preferred stock, issued	728,009		728,009
Preferred stock, shares outstanding	728,009	728,009	728,009

Statements of Operations (unaud

Statements of Operations (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	May 31, 2019	May 31, 2018	May 31, 2019	May 31, 2018
Income Statement [Abstract]
Revenue	$ 0	$ 0	$ 0	$ 0
Operating Expenses:
Research and development		459,584		749,584
Professional fees	8,205	80,980	17,039	289,170
General and administration	2,437	93,075	18,629	192,267
Total operating expenses	10,642	633,639	35,668	1,231,021
Operating Loss	(10,642)	(633,639)	(35,668)	(1,231,021)
Other Income (Expense):
Rental income		15,000	28,000	45,000
Gain on write off of accounts payable			23,629
Gain on disposition of Zander			188,589
Refund on amount previously paid			1,289
Interest Income				132
Loss on disposition Entest Biomedical			(6,947)
Interest expense		(361)	(495)	(1,025)
Total Other Income (Expense)		14,639	234,065	44,107
Net Income (Loss) Before Income Tax	(10,642)	(619,000)	198,397	(1,186,914)
Income tax provision	0	0	0	0
Net Income (Loss)	$ (10,642)	$ (619,000)	$ 198,397	$ (1,186,914)
Basic income (loss) per common share (in dollars per share)	$ 0	$ (0.01)	$ 0	$ (0.02)
Diluted income (loss) per common share (in dollars per share)	$ 0	$ (0.01)	$ 0	$ (0.02)
Weighted average number of common shares outstanding
Basic (in shares)	49,170,472	49,170,472	49,170,472	49,106,134
Diluted (in shares)	49,170,472	49,170,472	153,605,613	49,106,134

Statements of Stockholders' Def

Statements of Stockholders' Deficit (Unaudited) - USD ($)	Series AA Preferred	Series AAA Preferred	Series B Preferred	Non-Voting Convertible Preferred Convertible Preferred	Common Stock	Additional Paid In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Non-Controlling Interest In Subsidiary	Total
Beginning balance, Shares at Aug. 31, 2017	667	534	728,009	1,026,533	46,670,472
Beginning balance, Amount at Aug. 31, 2017			$ 73	$ 1,026,533	$ 4,667	$ 7,465,656	$ (8,721,496)	$ 185,050	$ 56,343	$ 16,826
Common Shares issued for conversion of Non-Voting Convertible Preferred Shares (Shares)				(25,000)	2,500,000
Common Shares issued for conversion of Non-Voting Convertible Preferred Shares				$ (25,000)	$ 250	24,750
Common Shares of subsidiary issued for cash						900,000				900,000
Accumulated other comprehensive income								43,750		43,750
Non Controlling Interest in Subsidiary						(228,345)			228,345
Net loss for the period							(158,106)			(158,106)
Ending balance, Shares at Nov. 30, 2017	667	534	728,009	1,001,533	49,170,472
Ending balance, Amount at Nov. 30, 2017			$ 73	$ 1,001,533	$ 4,917	(8,162,061)	(8,879,602)	228,800	284,688	802,470
Beginning balance, Shares at Aug. 31, 2017	667	534	728,009	1,026,533	46,670,472
Beginning balance, Amount at Aug. 31, 2017			$ 73	$ 1,026,533	$ 4,667	7,465,656	(8,721,496)	185,050	56,343	16,826
Net loss for the period										(1,186,914)
Ending balance, Shares at May. 31, 2018	667	534	728,009	1,001,533	49,170,472
Ending balance, Amount at May. 31, 2018			$ 73	$ 1,001,533	$ 4,917	8,837,070	(9,965,554)	72,700	109,679	60,418
Beginning balance, Shares at Nov. 30, 2017	667	534	728,009	1,001,533	49,170,472
Beginning balance, Amount at Nov. 30, 2017			$ 73	$ 1,001,533	$ 4,917	(8,162,061)	(8,879,602)	228,800	284,688	802,470
Common Shares of subsidiary issued for cash						200,000				200,000
Common Shares of subsidiary issued for cash						300,000				300,000
Accumulated other comprehensive income								(90,300)		(90,300)
Non Controlling Interest in Subsidiary						(71,210)			71,210
Net loss for the period							(409,809)			(409,809)
Ending balance, Shares at Feb. 28, 2018	667	534	728,009	1,001,533	49,170,472
Ending balance, Amount at Feb. 28, 2018			$ 73	$ 1,001,533	$ 4,917	8,590,851	(9,289,411)	138,500	355,898	802,361
Accumulated other comprehensive income								(65,800)		(65,800)
Non Controlling Interest in Subsidiary						(246,219)			246,219
Declaration of property Dividend May 5, 2018							(57,143)			(57,143)
Net loss for the period							(619,000)			(619,000)
Ending balance, Shares at May. 31, 2018	667	534	728,009	1,001,533	49,170,472
Ending balance, Amount at May. 31, 2018			$ 73	$ 1,001,533	$ 4,917	8,837,070	(9,965,554)	$ 72,700	$ 109,679	60,418
Beginning balance, Shares at Aug. 31, 2018	667	534	728,009	1,001,533	49,170,472
Beginning balance, Amount at Aug. 31, 2018			$ 73	$ 1,001,533	$ 4,917	9,003,892	(10,256,126)			(245,711)
Contributed Capital						21,422				21,422
Net loss for the period							220,011			220,011
Ending balance, Shares at Nov. 30, 2018	667	534	728,009	1,001,533	49,170,472
Ending balance, Amount at Nov. 30, 2018			$ 73	$ 1,001,533	$ 4,917	9,025,314	(10,036,115)			(4,278)
Beginning balance, Shares at Aug. 31, 2018	667	534	728,009	1,001,533	49,170,472
Beginning balance, Amount at Aug. 31, 2018			$ 73	$ 1,001,533	$ 4,917	9,003,892	(10,256,126)			(245,711)
Net loss for the period										198,397
Ending balance, Shares at May. 31, 2019	667	534	728,009	1,001,533	49,170,472
Ending balance, Amount at May. 31, 2019			$ 73	$ 1,001,533	$ 4,917	9,025,314	(10,057,729)			(25,892)
Beginning balance, Shares at Nov. 30, 2018	667	534	728,009	1,001,533	49,170,472
Beginning balance, Amount at Nov. 30, 2018			$ 73	$ 1,001,533	$ 4,917	9,025,314	(10,036,115)			(4,278)
Net loss for the period							(10,972)			(10,972)
Ending balance, Shares at Feb. 28, 2019	667	534	728,009	1,001,533	49,170,472
Ending balance, Amount at Feb. 28, 2019			$ 73	$ 1,001,533	$ 4,917	9,025,314	(10,047,087)			(15,250)
Net loss for the period							(10,642)			(10,642)
Ending balance, Shares at May. 31, 2019	667	534	728,009	1,001,533	49,170,472
Ending balance, Amount at May. 31, 2019			$ 73	$ 1,001,533	$ 4,917	$ 9,025,314	$ (10,057,729)			$ (25,892)

Statements of Cash Flows (unaud

Statements of Cash Flows (unaudited) - USD ($)	9 Months Ended
	May 31, 2019	May 31, 2018
Cash Flows From Operating Activities:
Net income (loss)	$ 198,397	$ (1,186,914)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Loss on disposition Entest Biomedical	6,947
Gain on write off of accounts payable	(23,629)
Gain on disposition of Zander	(188,589)
Expenses paid by a related party	13,627
Changes in operating assets and liabilities:
Accrued interest receivable		(132)
Accrued rental income receivable	(12,000)
Accounts payable and accrued expenses	1,018	218,849
Unearned rental income	(7,730)	20,000
Prepaid expenses	8,000	(117,388)
Net Cash Used In Operating Activities	(3,959)	(1,065,585)
CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash received for divestiture of Entest Biomedical	1,937
Net Cash Provided by Investing Activities	1,937
Cash Flows From Financing Activities:
Contributed capital	1,821
Proceeds from common stock issued from subsidiary		1,400,000
Repayment of bank overdraft	(66)
Proceed from notes payable		3,000
Net Cash Provided by Financing Activities	1,755	1,403,000
Net Change in Cash	(267)	337,415
Cash at Beginning of Period	267	86,559
Cash at End of Period		423,974
Supplemental Cash Flow Information:
Cash paid for interest	0	0
Cash paid for taxes	0	$ 0
Supplemental disclosure of non-cash financing activity
Debt Satisfied through Contributed Capital	$ 19,601

ORGANIZATION, DESCRIPTION OF BU

ORGANIZATION, DESCRIPTION OF BUSINESS, AND GOING CONCERN	9 Months Ended
	May 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION, DESCRIPTION OF BUSINESS, AND GOING CONCERN	NOTE 1. ORGANIZATION, DESCRIPTION OF BUSINESS, AND GOING CONCERN Entest Group, Inc. (the “Company” or “Entest”) was incorporated in the State of Nevada on September 24, 2008 as JB Clothing Corporation. On July 12, 2009, the Company changed its name to Entest BioMedical, Inc. On February 12, 2018 the Company changed its name from Entest BioMedical, Inc. to Entest Group, Inc. The Company’s current business strategy is to acquire an operating company seeking the perceived advantages of being a publicly held corporation. No assurance can be given that such an acquisition shall occur or, if such an acquisition were to occur, it would occur on terms and conditions beneficial to the Company or its shareholders. Change of Control On November 15, 2018, David Koos, Regen BioPharma Inc., Bostonia Partners Inc., Sherman Family Trust, Dunhill Ross Partners Inc., Bio-Technology Partners Business Trust (collectively, the “Sellers”) and Peiwen Yu (the “Buyer”) entered into a stock purchase agreement (the “SPA”), pursuant to which the Sellers agreed to sell and the Buyer agreed to purchase an aggregate of 23,733,334 shares of common stock, 667 shares of Series AA preferred stock, 534 shares of Series AAA preferred stock and 1,001,533 shares of Non-Voting Preferred Stock of Entest from the Seller for an aggregate purchase price of $325,000. The closing of the transactions contemplated by the SPA occurred on November 27, 2018. The purchase price was paid out of the Buyer’s personal funds. As of the date of the transaction, Entest had 49,170,472 shares of common stock, 728,009 shares of Series B Preferred Stock, 667 shares of Series AA Preferred Stock, 534 shares of Series AAA Preferred Stock and 1,001,533 shares of Non-Voting Convertible Preferred Stock outstanding. The securities purchased pursuant to the SPA represent 48.3% of the outstanding shares of common stock, 90% of the outstanding shares of common stock assuming the conversion of the Non-Voting Convertible Preferred Stock on the execution date of the SPA and 94% of the voting power of Entest. As contemplated by the SPA, in November 2018, David Koos resigned as Chairman, Chief Executive Officer, President, Acting Chief Financial Officer and Secretary of Entest and Peiwen Yu became as a director, Chief Executive Officer and President of Entest. Pursuant to the SPA, in November 2018, Mr. Koos also resigned as a director of the Company upon compliance by Entest with information statement delivery requirements pursuant to Rule 14f-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Going Concern and Liquidity Considerations The accompanying unaudited interim financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any revenues since the change of control and disposition of its subsidiaries, and has an accumulated deficit of $10,057,729. These factors among others raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. The continuing operations of the Company are dependent upon its ability to continue to raise adequate financing and to commence profitable operations in the future and repay its liabilities arising from normal business operations as they become due. In support of the Company’s efforts and cash requirements, it may rely on advances from related parties until such time that the Company can support its operations or attains adequate financing through sales of its equity or traditional debt financing. There is no formal written commitment for continued support by shareholders or directors.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	May 31, 2019
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of May 31, 2019 and the results of operations, statements of changes in stockholders’ deficit and cash flows for the periods presented. The results of operations for the period ended May 31, 2019 are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited interim financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended August 31, 2018 filed with the Securities and Exchange (the “SEC”) on November 28, 2018. Reclassifications Certain prior year amounts have been reclassified to conform with the current year presentation. Recent Accounting Pronouncements In October 2018, FASB issued ASU No. 2018-17, Consolidation - Targeted Improvements to Related Party Guidance for Variable Interest Entities (Topic 810).

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	May 31, 2019
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 3. RELATED PARTY TRANSACTIONS On July 3, 2018, Zander entered into a sublease agreement with Entest whereby Zander would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from Entest on a month to month basis for $6,000 per month beginning July 5, 2018. On November 16, 2018 Zander Therapeutics Inc. and the Company agreed to terminate Zander’s sublease with the Company effective the rental period commencing November, 2018. David R. Koos, who served as Chairman and Chief Executive Officer of Zander as of that date also served as Chairman and Chief Executive Officer of Entest as of that date. Zander was under common control with Entest as of that date. On November 16, 2018, Entest Group, Inc. and its then Chairman and Chief Executive Officer, David R. Koos, agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to Koos by Entest from the beginning of time to November 30, 2018 by transferring to David R. Koos 3,000,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. Entest Group, Inc. and Blackbriar Partners (“BP”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BP by Entest from the Company’s inception to November 30, 2018 by transferring to BP 20,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. BP is controlled by David Koos, as of that date, the Company’s then Chairman and Chief Executive Officer. Entest Group, Inc. and the Bio Matrix Scientific Group, Inc. (“BMSN”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BMSN by Entest from the Company’s inception to November 30, 2018 by transferring to BMSN 5,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. As of November 16, 2018, David R. Koos was the Chairman and Chief Executive Officer of the Company and BMSN. Entest Group, Inc. and Regen Biopharma, Inc. (“RGBP”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to RGBP by Entest from the beginning of time to November 30, 2018 by transferring to RGBP 250,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. Entest Group, Inc. and Regen Biopharma, Inc. (“RGBP”) agreed to satisfy any and all rent prepaid by RGBP to Entest from the beginning of time to November 30, 2018 by transferring to RGBP 475,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. As of November 16, 2018, David R. Koos was the Chairman and Chief Executive Officer of the Company and RGBP. In November 2018, the Company divested itself of Entest BioMedical, Inc., a California corporation, for consideration consisting of $2,000 paid by an entity controlled by David R. Koos. The Company recognized a loss of $6,947 on the disposition based on the difference between the Net Assets of the subsidiary and the consideration paid. During the period ended May 31, 2019, the Company’s sole officer advanced to the Company an amount of $13,627 by issuing an unsecured and non-interest bearing loan that is payable on demand. As of May 31, 2019 and August 31, 2018, the balance of such loan was $13,627 and $0, respectively.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	May 31, 2019
Stockholders' Deficit
STOCKHOLDERS' EQUITY	NOTE 4. STOCKHOLDERS’ EQUITY Authorized Stock The Company is authorized to issue an aggregate of 500,000,000 shares of common stock with a par value of $0.0001, 5,000,000 shares of preferred stock with a par value of $0.0001, and 3,000,000 shares of non-voting convertible preferred stock with a par value of $1.00. Each share of common stock entitles the holder to one vote on any matter on which action of the stockholders of the corporation is sought. Series AA Preferred Stock The Company is authorized to issue 100,000 shares of Series AA Preferred Stock at a par value of $0.0001 per share. As of May 31, 2019 and August 31, 2018, 667 shares of Series AA Preferred Stock were issued and outstanding. Series B Preferred Stock The Company is authorized to issue 4,400,000 shares of Series B Preferred Stock at a par value of $0.0001 per share. As of May 31, 2019 and August 31, 2018, 728,009 shares of Series B Preferred Stock were issued and outstanding. Series AAA Preferred Stock The Company is authorized to issue 300,000 shares of Series AAA Preferred Stock at a par value of $0.0001 per share. As of May 31, 2019 and August 31, 2018, 534 shares of Series AAA Preferred Stock were issued and outstanding. Non-Voting Convertible Preferred Stock The Company is authorized to issue 3,000,000 shares of Non-Voting Convertible Preferred Stock at a par value of $1.00 per share. On October 2, 2018, the Company amended Article 4 of its Articles of Incorporation to change the conversion features of the Company’s Non -Voting Convertible Preferred Stock. The Conversion Price changed from being equal to the greater of $0.01 per share or seventy percent (70%) of the lowest closing bid price of its shares of common stock (the “Closing Price”) on its principal trading market or exchange for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert to being equal to the greater of (i) $0.001 per share and (ii) seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert. As of May 31, 2019 and August 31, 2018, 1,001,533 shares of Non-Voting Convertible Preferred Stock were issued and outstanding. Common Shares The Company is authorized to issue 500,000,000 shares of Common Stock at a par value of $0.0001 per share. As of May 31, 2019 and August 31, 2018, 49,170,472 shares of Common Stock were issued and outstanding.

DECONSOLIDATION OF ZANDER THERA

DECONSOLIDATION OF ZANDER THERAPEUTICS, INC.	9 Months Ended
	May 31, 2019
Notes to Financial Statements
DECONSOLIDATION OF ZANDER THERAPEUTICS, INC.	NOTE 4. DECONSOLIDATION OF ZANDER THERAPEUTICS, INC. On May 5, 2018, The Company declared the distribution on a pro rata basis as a dividend in kind of 3,000,000 of the common shares of Zander Therapeutics, Inc., par value $0.0001, currently owned by Entest Group, Inc. to: (a) Holders of record of the outstanding common shares of the Company as of the record date, which is May 30, 2018. (b) Holders of record of the shares of any outstanding series of the preferred shares of the Company as of the record date, which is May 30, 2018. Shareholders of the Company shall receive one (1) share of common stock of Zander Therapeutics, Inc. for each 17 shares of the Company’s common and/or preferred stock held as of the record date for such dividend. The distribution of the 3,000,000 common shares of Zander Therapeutics, Inc. to the common and preferred shareholders of the Company occurred on June 11, 2018 (“Distribution Date”). As a result of the payment of the abovementioned property dividend, the Company’s percentage of ownership of Zander fell below 50% resulting in the deconsolidation of Zander as of the Distribution Date. As of the Distribution Date all assets and liabilities attributable to Zander were derecognized by the Company. The Company recognized a $10,034 gain as a result of the deconsolidation. The Property dividend may be deemed to have occurred with a related party as the recipients were shareholders of Entest, including the then Chairman and Chief Executive Officer of Entest and Regen Biopharma, Inc. which was a company under common control with Entest. The Company’s remaining shares of Zander, which consisted of 5,000,000 shares of Zander’s Series M Preferred Stock (“Zander M Stock”) were accounted for under the Equity Method as of the Distribution Date until November 29, 2018. The Zander M Stock was carried a Fair Value and the carrying value was increased by the Company’s proportionate share of earnings of Zander and decreased by cash dividends paid by Zander as well as the Company’s proportionate share of losses of Zander up to the carrying value. As of August 31, 2018, the carrying value of the Zander M Stock was decreased by the Company’s proportionate share of the losses of Zander and was 0. As of August 31, 2018, Entest beneficially owned 34.82% of the share equity of Zander. During the quarter ended November 30, 2018, the Company divested itself of the Zander M Stock as satisfaction of $179,318 of interest accrued but unpaid owed by the Company and $9,270 of unearned rental payments made to the Company. As the Zander M Stock had a carrying value of $0, the Company recognized a gain of $188,589 on the disposition.

DISPOSITION OF ENTEST BIOMEDICA

DISPOSITION OF ENTEST BIOMEDICAL, INC., A CALIFORNIA CORPORATION	9 Months Ended
	May 31, 2019
Disposition Of Entest Biomedical Inc. California Corporation
DISPOSITION OF ENTEST BIOMEDICAL, INC., A CALIFORNIA CORPORATION	NOTE 5. DISPOSITION OF ENTEST BIOMEDICAL, INC., A CALIFORNIA CORPORATION During the quarter ended November 30, 2018 the Company divested itself of Entest Biomedical, Inc., a California corporation and wholly owned subsidiary, for consideration consisting of $2,000 paid by an entity controlled by the Company’s then Chairman and Chief Executive Officer, David R. Koos, as full consideration for Entest Biomedical Inc. as well as any and all furniture, fixtures and equipment owned by the Company which has a carrying amount of $0. The Company recognized a loss of $6,947 on the disposition based on the difference between the Net Assets of the subsidiary and the Consideration paid. Cash derecognized in Divestiture $ (63 ) Accrued Rent Receivable Derecognized in Divestiture $ (12,000 ) Liabilities Derecognized in Divestiture $ 3,116 Consideration Received in Divestiture $ 2,000 Loss Recognized in Divestiture $ (6,947 )

INCOME TAXES

INCOME TAXES	9 Months Ended
	May 31, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 6. INCOME TAXES The Company provides for income taxes under ASC 740, “Income Taxes.” The income tax provision for the periods ended May 31, 2019 and 2018, consists of the following: May 31, May 31, 2019 2018 Net income (loss) $ 198,397 $ (1,186,914 ) Effective tax rate 21 % 21 % Income tax expense (benefit) 41,663 (249,252 ) Less: valuation allowance (41,663 ) 249,252 Income tax expense (benefit) $ - $ - Net deferred tax assets consist of the following components as of May 31, 2019 and August 31, 2018: May 31, August 31, 2019 2018 Net operating tax carryforwards $ 2,114,989 $ 2,156,652 Valuation allowance (2,114,989 ) (2,156,652 ) Net deferred tax asset $ - $ - On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the “Act”) resulting in significant modifications to existing law including lowering the corporate tax rate from 34% to 21%. In addition to applying the new lower corporate tax rate in 2018 and thereafter to any taxable income we may have, the legislation affects the way we can use and carry forward net operating losses previously accumulated and results in a revaluation of deferred tax assets and liabilities recorded on our balance sheet. The Company has completed the accounting for the effects of the Act during the period ended May 31, 2019. Given that current deferred tax assets are offset by a full valuation allowance, these changes will have no impact on the balance sheet. As of May 31, 2019, the Company had approximately $10,071,376 of net operating loss (“NOL”) carry forwards, the tax effect of which is approximately $2,114,989. These carry forwards begin to expire in 2029. The NOL carry forwards are subject to certain limitations due to the change in control of the Company pursuant to Internal Revenue Code Section 382. The Company experienced a change in control for tax purposes in November 2018 (see Note 1). The Company has not performed a study to determine if the NOL carry forwards are subject to these Section 382 limitations.

EARNING (LOSS) PER SHARE

EARNING (LOSS) PER SHARE	9 Months Ended
	May 31, 2019
Earnings Per Share [Abstract]
EARNING (LOSS) PER SHARE	NOTE 7 - EARNING (LOSS) PER SHARE The following is a reconciliation of the numerator and denominator used in the basic and diluted earnings per share ("EPS") calculations. Three Months Ended Nine Months Ended May 31, May 31, 2019 2018 2019 2018 Numerator: Net income (loss) $ (10,642 ) $ (619,000 ) $ 198,397 $ (1,186,914 ) Earnings allocated to participating securities - - - - Income (loss) available to common stockholders $ (10,642 ) $ (619,000 ) $ 198,397 $ (1,186,914 ) Denominator: Weighted-average shares of common stock 49,170,472 49,170,472 49,170,472 49,106,134 Dilutive effect of convertible instruments - - 104,435,141 - Diluted weighted-average of common stock 49,170,472 49,170,472 153,605,613 49,106,134 Net income (loss) per common share from: Basic: $ (0.00 ) $ (0.01 ) $ 0.00 $ (0.02 ) Diluted: $ (0.00 ) $ (0.01 ) $ 0.00 $ (0.02 ) For the three months ended May 31, 2019 and periods ended May 31, 2018, the convertible instruments are anti-dilutive and therefore, have been excluded from earnings (loss) per share. For the nine months ended May 31, 2019, diluted earnings per share is calculated using net income available to common stockholders divided by the diluted weighted average number of common shares outstanding during each period determined using the if-converted method.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	May 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8 - SUBSEQUENT EVENTS Management has evaluated subsequent events through the date these financial statements were available to be issued. Based on our evaluation no material events have occurred that require disclosure.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	May 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of May 31, 2019 and the results of operations, statements of changes in stockholders’ deficit and cash flows for the periods presented. The results of operations for the period ended May 31, 2019 are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited interim financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended August 31, 2018 filed with the Securities and Exchange (the “SEC”) on November 28, 2018.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified to conform with the current year presentation.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In October 2018, FASB issued ASU No. 2018-17, Consolidation - Targeted Improvements to Related Party Guidance for Variable Interest Entities (Topic 810).

DISPOSITION OF ENTEST BIOMEDI_2

DISPOSITION OF ENTEST BIOMEDICAL, INC., A CALIFORNIA CORPORATION (Tables)	9 Months Ended
	May 31, 2019
Disposition Of Entest Biomedical Inc. California Corporation
Schedule of disposion	Cash derecognized in Divestiture $ (63 ) Accrued Rent Receivable Derecognized in Divestiture $ (12,000 ) Liabilities Derecognized in Divestiture $ 3,116 Consideration Received in Divestiture $ 2,000 Loss Recognized in Divestiture $ (6,947 )

INCOME TAXES (Tables)

INCOME TAXES (Tables)	9 Months Ended
	May 31, 2019
Income Tax Disclosure [Abstract]
Schedule of income tax provision	May 31, May 31, 2019 2018 Net income (loss) $ 198,397 $ (1,186,914 ) Effective tax rate 21 % 21 % Income tax expense (benefit) 41,663 (249,252 ) Less: valuation allowance (41,663 ) 249,252 Income tax expense (benefit) $ - $ -
Schedule of deferred tax assets	May 31, August 31, 2019 2018 Net operating tax carryforwards $ 2,114,989 $ 2,156,652 Valuation allowance (2,114,989 ) (2,156,652 ) Net deferred tax asset $ - $ -

EARNING (LOSS) PER SHARE (Table

EARNING (LOSS) PER SHARE (Tables)	9 Months Ended
	May 31, 2019
Earnings Per Share [Abstract]
Schedule of earnings per share	Three Months Ended Nine Months Ended May 31, May 31, 2019 2018 2019 2018 Numerator: Net income (loss) $ (10,642 ) $ (619,000 ) $ 198,397 $ (1,186,914 ) Earnings allocated to participating securities - - - - Income (loss) available to common stockholders $ (10,642 ) $ (619,000 ) $ 198,397 $ (1,186,914 ) Denominator: Weighted-average shares of common stock 49,170,472 49,170,472 49,170,472 49,106,134 Dilutive effect of convertible instruments - - 104,435,141 - Diluted weighted-average of common stock 49,170,472 49,170,472 153,605,613 49,106,134 Net income (loss) per common share from: Basic: $ (0.00 ) $ (0.01 ) $ 0.00 $ (0.02 ) Diluted: $ (0.00 ) $ (0.01 ) $ 0.00 $ (0.02 )

ORGANIZATION, DESCRIPTION OF _2

ORGANIZATION, DESCRIPTION OF BUSINESS, AND GOING CONCERN (Details Narrative) - USD ($)	1 Months Ended
	Nov. 15, 2018	May 31, 2019	Aug. 31, 2018
Number of common stock issued		49,170,472	49,170,472
Number of preferred stock issued		5,000,000
Common stock, shares outstanding	49,170,472	49,170,472	49,170,472
Accumulated deficit		$ (10,057,729)	$ (10,256,126)
Series AA
Number of preferred stock issued		667	667
Preferred stock, shares outstanding	667	667	667
Series AAA
Number of preferred stock issued		534	534
Preferred stock, shares outstanding	534	534	534
Non-Voting
Number of preferred stock issued		1,001,533	1,001,533
Preferred stock, shares outstanding	1,001,533	1,001,533	1,001,533
Series B
Number of preferred stock issued		728,009	728,009
Preferred stock, shares outstanding	728,009	728,009	728,009
Stock purchase agreement (the "SPA"), | Peiwen Yu (the "Buyer")
Number of common stock issued	23,733,334
Purchase price	$ 325,000
Stock purchase agreement (the "SPA"), | Peiwen Yu (the "Buyer") | Series AA
Number of preferred stock issued	667
Stock purchase agreement (the "SPA"), | Peiwen Yu (the "Buyer") | Series AAA
Number of preferred stock issued	534
Stock purchase agreement (the "SPA"), | Peiwen Yu (the "Buyer") | Non-Voting
Number of preferred stock issued	1,001,533
Stock purchase agreement (the "SPA"), | Peiwen Yu (the "Buyer") | Common Stock
Percentage of Stock outstanding	48.30%
Stock purchase agreement (the "SPA"), | Peiwen Yu (the "Buyer") | Common stock and non-voting convertible preferred stock
Percentage of Stock outstanding	90.00%
Stock purchase agreement (the "SPA"), | Peiwen Yu (the "Buyer") | Voting common stock
Percentage of Stock outstanding	94.00%

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Jul. 03, 2018	Nov. 30, 2018	Nov. 30, 2018	May 31, 2019	Nov. 30, 2018
Loss on disposition			$ (6,947)	$ 188,589
Divestiture consideration			$ 2,000
Due to related party				13,627
Unsecured and non-interest bearing loan
Due to related party				$ 13,627
David R. Koos | Zander M stock
Number of shares issued		3,000,000
Zander Therapeutics, Inc.
Monthly sublease income	$ 6,000
Blackbriar Partners ("BP") | Zander M stock
Number of shares issued					20,000
Bio Matrix Scientific Group, Inc. ("BMSN") | Zander M stock
Number of shares issued					5,000
Regen Biopharma, Inc. ("RGBP") | Zander M stock
Number of shares issued		250,000
Number of shares issued for prepaid rent		475,000

STOCKHOLDERS' EQUITY (Details N

STOCKHOLDERS' EQUITY (Details Narrative) - $ / shares	Oct. 02, 2018	May 31, 2019	Nov. 15, 2018	Aug. 31, 2018
Common stock, par value		$ 0.0001		$ 0.0001
Common stock, authorized		500,000,000		500,000,000
Common stock, issued		49,170,472		49,170,472
Common stock, shares outstanding		49,170,472	49,170,472	49,170,472
Preferred stock, par value		$ 0.0001
Preferred stock, issued		5,000,000
Non-Voting Convertible Preferred Stock
Preferred stock, authorized		3,000,000		3,000,000
Preferred stock, par value		$ 1		$ 1
Preferred stock, issued		1,001,533		1,001,533
Preferred stock, shares outstanding		1,001,533	1,001,533	1,001,533
Conversion price reduction due to closing bid price (in dollar per share)	$ 0.01
Conversion price equals average closing bid price (percent)	70.00%
Number of consecutive trading days	5 days
Series AA
Preferred stock, authorized		100,000		100,000
Preferred stock, par value		$ 0.0001		$ 0.0001
Preferred stock, issued		667		667
Preferred stock, shares outstanding		667	667	667
Series B
Preferred stock, authorized		4,400,000		4,400,000
Preferred stock, par value		$ 0.0001		$ 0.0001
Preferred stock, issued		728,009		728,009
Preferred stock, shares outstanding		728,009	728,009	728,009
Series AAA
Preferred stock, authorized		300,000		300,000
Preferred stock, par value		$ 0.0001		$ 0.0001
Preferred stock, issued		534		534
Preferred stock, shares outstanding		534	534	534

DECONSOLIDATION OF ZANDER THE_2

DECONSOLIDATION OF ZANDER THERAPEUTICS, INC. (Details Narrative) - USD ($)	May 05, 2018	Nov. 30, 2018	Aug. 31, 2018	May 31, 2019
Common stock, par value			$ 0.0001	$ 0.0001
Interest accrued			$ 1,040	$ 1,040
Zander M stock
Gain on deconsolidation		$ 188,589
Equity method stock remaining	5,000,000
Carrying value		0	$ 0
Zander Therapeutics, Inc.
Dividend in kind	3,000,000
Common stock, par value	$ 0.0001
Record date	May 30, 2018
Distribution date	Jun. 11, 2018
Gain on deconsolidation	$ 10,034
Ownership percentage			34.82%
Interest accrued		179,318
Unearned rental payments		$ 9,270
Common stock distribution description	one (1) share of common stock of Zander Therapeutics, Inc. for each 17 shares of the Company's common and/or preferred stock

DISPOSITION OF ENTEST BIOMEDI_3

DISPOSITION OF ENTEST BIOMEDICAL, INC., A CALIFORNIA CORPORATION (Details) - USD ($)	3 Months Ended	9 Months Ended
	Nov. 30, 2018	May 31, 2019
Consideration Received in Divestiture	$ 2,000
Loss Recognized in Divestiture	(6,947)	$ 188,589
Entest Biomedical, Inc.
Cash derecognized in Divestiture	(63)
Accrued Rent Receivable Derecognized in Divestiture	(12,000)
Liabilities Derecognized in Divestiture	3,116
Consideration Received in Divestiture	2,000
Loss Recognized in Divestiture	$ (6,947)

DISPOSITION OF ENTEST BIOMEDI_4

DISPOSITION OF ENTEST BIOMEDICAL, INC., A CALIFORNIA CORPORATION (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Nov. 30, 2018	May 31, 2019
Disposition Of Entest Biomedical Inc. California Corporation
Divestiture consideration	$ 2,000
Loss on disposition	(6,947)	$ 188,589
Furniture fixtures and equipment carrying amount	$ 0

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	3 Months Ended						9 Months Ended
	May 31, 2019	Feb. 28, 2019	Nov. 30, 2018	May 31, 2018	Feb. 28, 2018	Nov. 30, 2017	May 31, 2019	May 31, 2018
Income Taxes
Net income (loss)	$ (10,642)	$ (10,972)	$ 220,011	$ (619,000)	$ (409,809)	$ (158,106)	$ 198,397	$ (1,186,914)
Effective tax rate							21.00%	21.00%
Income tax expense (benefit)							$ 41,663	$ (249,252)
Less: valuation allowance							(41,663)	249,252
Income tax expense (benefit)							$ 0	$ 0

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	May 31, 2019	Aug. 31, 2018
Income Tax Disclosure [Abstract]
Net operating tax carryforwards	$ 2,114,989	$ 2,156,652
Valuation allowance	(2,114,989)	(2,156,652)
Net deferred tax asset	$ 0	$ 0

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	9 Months Ended
	May 31, 2019	Aug. 31, 2018
Income Tax [Line Items]
Net operating loss carry forwards	$ 10,071,376
Deferred tax asset	$ 2,114,989	$ 2,156,652
Description of carry forwards expiry year	These carry forwards begin to expire in 2029.
Previous Tax Year
Income Tax [Line Items]
Effective interest tax rate	34.00%
Current Tax Year
Income Tax [Line Items]
Effective interest tax rate	21.00%

EARNING (LOSS) PER SHARE (Detai

EARNING (LOSS) PER SHARE (Details) - USD ($)	3 Months Ended						9 Months Ended
	May 31, 2019	Feb. 28, 2019	Nov. 30, 2018	May 31, 2018	Feb. 28, 2018	Nov. 30, 2017	May 31, 2019	May 31, 2018
Numerator:
Net income (loss)	$ (10,642)	$ (10,972)	$ 220,011	$ (619,000)	$ (409,809)	$ (158,106)	$ 198,397	$ (1,186,914)
Earnings allocated to participating securities	0			0			0	0
Income (loss) available to common stockholders	$ (10,642)			$ (619,000)			$ 198,397	$ (1,186,914)
Denominator:
Weighted-average shares of common stock	49,170,472			49,170,472			49,170,472	49,106,134
Dilutive effect of convertible instruments	0			0			104,435,141	0
Diluted weighted-average of common stock	49,170,472			49,170,472			153,605,613	49,106,134
Net income (loss) per common share from:
Basic:	$ 0			$ (0.01)			$ 0	$ (0.02)
Diluted:	$ 0			$ (0.01)			$ 0	$ (0.02)